| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF909-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB901-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-13173SS | |||
| Azide and BSA Free | NBP2-80855 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1488-SP | |||
![N/A MMP-9 [HRP]](http://images.novusbio.com/fullsize2/DATA_MMP9_DMP900_ELISA_770.jpg "N/A MMP-9 [HRP]")
![N/A MMP-9 [HRP]](http://images.novusbio.com/fullsize2/MMP-9_DMP900_ELISA_148.jpg)
![N/A MMP-2 [HRP]](http://images.novusbio.com/fullsize2/DATA_MMP2_MMP200_ELISA_1003.jpg "N/A MMP-2 [HRP]")
![N/A MMP-2 [HRP]](http://images.novusbio.com/fullsize2/MMP2_MMP200_ELISA_474.jpg)
![N/A MMP-9 [Biotin]](http://images.novusbio.com/fullsize2/DATA_MMP9_DY911_ELISA_2261.jpg "N/A MMP-9 [Biotin]")
![N/A MMP-3 [HRP]](http://images.novusbio.com/fullsize2/DATA_MMP3_DMP300_ELISA_767.jpg "N/A MMP-3 [HRP]")
![N/A MMP-3 [HRP]](http://images.novusbio.com/fullsize2/MMP-3_DMP300_ELISA_145.jpg)
![Expression of MMP1 on gene and protein levels upon treatment with mitomycin C (MMC) of SKOV3 cells in normoxia and hypoxia. MMP1 gene expression was measured using (A) HTA 2.0 microarrays and (B) RT-qPCR [normalized to PPIA and GUSB levels and normoxia control (NC) as 1]. (C) Immunoblot of MMP 1 protein (with vinculin as loading control). (D) Quantification of MMP1 protein levels by densitometry. (E) Secretion of pro-MMP1 protein levels measured by ELISA.(F) Secretion of total MMP1 protein levels measured by ELISA. (B,D) Results were normalized to normoxia control as 1. ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05; VIN, vinculin. A detailed statistics description is provided in the Supplementary Table S2. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/40584967), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/mab901_human-mmp-1-mab-clone-36665-western-blot-121220259313310.jpg)
![Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - Analysis of activated MMP9 expression in MMP9 proenzyme incubated with trypsin for various times.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Western-Blot-NBP2-13173-img0002.jpg "Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - Analysis of activated MMP9 expression in MMP9 proenzyme incubated with trypsin for various times.")
![Immunohistochemistry: MMP-9 Antibody (4A3) [NBP2-13173] - MMP-9 (green) was detected in murine brain (cortex) using MMP-9-DyLight 488 (4A3) with a concentration of 1:20 in PBS for 2 hours. MMP9-Signals are overlaped with the corresponding phase contrast image. Image from verified customer review. Image using the FITC format of this antibody.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Immunohistochemistry-NBP2-13173-img0006.jpg)
![Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - Identification of gelatinases by Western blot analysis. A pool of sera from 10 patients with inactive RR-MS was used. For 2-DZ, pooled sera were concentrated 10-fold and 40 ug of total proteins were applied (left panels). For Western blot analysis pooled sera were concentrated 40-fold and 160 ug of total proteins were subjected to 2-DE (right panels). 2-DE gels were cut and the corresponding nitrocellulose membranes were treated with anti-NGAL Ab (A'), anti-MMP-2 Ab (B') and Anti-MMP-9 (4A3) Ab, recognizing the 65 kD and the 82 kD activated forms (C'); Gel C show the region with isoelectric point between pH 4-5.5 and molecular mass between 85 and 55 kD, analysed by Western blot in C', respectively. Image collected and cropped by CiteAb from the following publication (null), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Western-Blot-NBP2-13173-img0011.jpg)
![Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - 1-DZ analysis and identification of gelatinases by Western blot. 1.5 ul of serum from healthy control (HC) or from a patient with inactive RR-MS were loaded on a 7.5% polyacrylamide gel copolymerized with 0.1% (w/v) gelatin (1-DZ). For Western blot analysis, 2 ul of fivefold concentrated (Vivaspin 500, MWCO 50,000; GE Healthcare) serum samples (the same as in 1-DZ) were separated on a 7.5% polyacrylamide gel without gelatin (1-DE), transferred on nitrocellulose membranes and incubated with the following primary antibodies: Anti-NGAL Antibody (5G5) at concentration of 2.0 ug/ml; Anti-MMP-9 (Ab-8) Mouse mAb (IA5) at concentration of 2.66 ug/ml; Anti-MMP-2 (Ab-4) Mouse mAb (75-7F7) at concentration of 1.0 ug/ml and Anti-MMP-9 Ab (4A3) at concentration of 2.0 ug/ml. Image collected and cropped by CiteAb from the following publication (null), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Western-Blot-NBP2-13173-img0012.jpg)
![Immunohistochemistry-Paraffin: MMP-9 Antibody (4A3) [NBP2-13173] - Analysis of a FFPE tissue section of human esophageal cancer using MMP9 antibody (clone 4A3) at 1:200. The staining was developed with HRP-labelled secondary antibody and DAB reagent followed by hematoxylin counterstaining. This antibody generated a specific extracellular and cytoplasmic staining primarily in the cancer cells while the signal was pretty weak in the tumor stroma.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Immunohistochemistry-Paraffin-NBP2-13173-img0003.jpg)
![Immunohistochemistry-Paraffin: MMP-9 Antibody (4A3) [NBP2-13173] - Analysis of a FFPE section of human esophageal cancer using MMP9 antibody (clone 4A3) at 1:200. The staining was developed with HRP-labelled secondary antibody and DAB reagent followed by hematoxylin counterstaining. This antibody clone generated an extracellular and cytoplasmic staining mainly in the cancer cells while the signal was very weak in the stromal cells of the tumor.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Immunohistochemistry-Paraffin-NBP2-13173-img0004.jpg)
![Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - 2-DZ analysis & identification of MMP-9 by Western blot. Left panels (A & B): 2-D zymography (2-DZ) of serum samples from healthy control (A) & from an inactive RR-MS patient not subjected to therapy (same patient as in Fig. 2; B). For 2-DZ, aliquots of 35 μl of serum were resuspended in the rehydration solution & subjected to isoelectrofocusing (IEF; 1st dimension) on IPG Dry-Strips of 13 cm in a linear pH gradient of 4–7. After IEF, IPG strips were equilibrated & then applied for the 2nd dimension in a 8.5% (w/v) polyacrylamide gel copolymerized with 0.1% (w/v) gelatin. The isoforms & charge variants of MMP-2 & MMP-9 appear as clear spots of digestion on the dark background of the gel. Right panels (A' & B') represent Western blot analysis of the same sera shown in A & B. Aliquots of 35 μl of serum samples (instead of the usual 20 μl) were subjected to 2D electrophoresis (2-DE) by using 8.5% (w/v) polyacrylamide gels without gelatin. After transfer of the proteins, the nitrocellulose membranes were incubated with an anti MMP-9 (Ab-8) Mouse mAb (IA5) at concentration of 2.66 μg/ml. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24616914), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-13173_mouse-monoclonal-mmp-9-antibody-4a3-31020241612243.jpg)
![Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - 2-DZ analysis & identification of MMP-9 by Western blot. Left panels (A & B): 2-D zymography (2-DZ) of serum samples from healthy control (A) & from an inactive RR-MS patient not subjected to therapy (same patient as in Fig. 2; B). For 2-DZ, aliquots of 35 μl of serum were resuspended in the rehydration solution & subjected to isoelectrofocusing (IEF; 1st dimension) on IPG Dry-Strips of 13 cm in a linear pH gradient of 4–7. After IEF, IPG strips were equilibrated & then applied for the 2nd dimension in a 8.5% (w/v) polyacrylamide gel copolymerized with 0.1% (w/v) gelatin. The isoforms & charge variants of MMP-2 & MMP-9 appear as clear spots of digestion on the dark background of the gel. Right panels (A' & B') represent Western blot analysis of the same sera shown in A & B. Aliquots of 35 μl of serum samples (instead of the usual 20 μl) were subjected to 2D electrophoresis (2-DE) by using 8.5% (w/v) polyacrylamide gels without gelatin. After transfer of the proteins, the nitrocellulose membranes were incubated with an anti MMP-9 (Ab-8) Mouse mAb (IA5) at concentration of 2.66 μg/ml. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24616914), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-13173_mouse-monoclonal-mmp-9-antibody-4a3-310202416114778.jpg)
![N/A MMP-1 [HRP]](http://images.novusbio.com/fullsize2/DATA_MMP1_DMP100_ELISA_765.jpg "N/A MMP-1 [HRP]")
![N/A MMP-1 [HRP]](http://images.novusbio.com/fullsize2/DATA_MMP1_DMP100_ELISA_766.jpg)
![N/A MMP-1 [HRP]](http://images.novusbio.com/fullsize2/MMP-1_DMP100_ELISA_143.jpg)
![N/A MMP-9 [HRP]](http://images.novusbio.com/fullsize2/DATA_MMP9_MMPT90_ELISA_1006.jpg "N/A MMP-9 [HRP]")
![N/A MMP-9 [HRP]](http://images.novusbio.com/fullsize2/MMP-9_MMPT90_ELISA_296.jpg)
![N/A MMP-7 [HRP]](http://images.novusbio.com/fullsize2/DATA_MMP7_DMP700_ELISA_768.jpg "N/A MMP-7 [HRP]")
![N/A MMP-7 [HRP]](http://images.novusbio.com/fullsize2/MMP7_DMP700_ELISA_498.jpg)